Loading...
Market
How will Novo Nordisk's stock price react to new Wegovy clinical trial results by Dec 31, 2024?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Closing stock price on a specified financial market platform like NASDAQ
Story
Novo Nordisk's Wegovy with Semaglutide Reduces Heart Failure and COVID-19 Risks by Up to 29%
Aug 30, 2024, 09:14 AM
Novo Nordisk's Wegovy, containing semaglutide, has been shown to reduce the risk of severe complications in patients with a common form of heart failure, according to a new analysis. Research indicates that semaglutide, found in both Ozempic and Wegovy, can decrease the risk of heart failure events and cardiovascular death by up to 29%. A study involving 3,533 diabetic patients highlighted a 27% lower risk of heart-related complications. Additionally, a Harvard study suggests that these medications also reduce the risk of severe COVID-19 in individuals with obesity. The SELECT trial further supports these findings, showing reduced COVID-19-associated morbidity and mortality.
View original story
Similar markets
Significant increase (>10%) • 25%
Moderate increase (5-10%) • 25%
No significant change • 25%
Decrease • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No significant change or decrease • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%